Since heart‐specific PGC‐1α overexpression exhibits dilated myopathy in mice (Lehman et al., 2000), this plausible adverse effect in the heart should be considered when developing therapeutic agents targeting PGC‐1α. This evidence concerns the gene PPARGC1A and myopathy.